PedAM
Pediatric Disease Annotations & Medicines
| Disease | primary myelofibrosis |
| Phenotype | C0001815|myeloid metaplasia |
| Sentences | 12 |
| PubMedID- 24880208 | Essential thrombocytosis (et) falls under the umbrella of myeloproliferative disorders, which also includes chronic myelogenous leukemia, polycythemia vera, and myelofibrosis with myeloid metaplasia. |
| PubMedID- 21870730 | [myeloid metaplasia with myelofibrosis associated with acute coronary syndrome. |
| PubMedID- 21224796 | The role of splenectomy in myelofibrosis with myeloid metaplasia. |
| PubMedID- 20615740 | Objective: lenalidomide (ldm) is an immunomodulatory and anti-angiogenic drug which has been shown to be effective in several haematological disorders (multiple myeloma [mm], myeloid metaplasia with myelofibrosis [mf] and myelodysplastic syndrome [mds]). |
| PubMedID- 19785025 | Chronic idiopathic myelofibrosis with myeloid metaplasia presenting as refractory ascites. |
| PubMedID- 22282696 | Increase in fibrosis is due to liberation of cytokines such as tgf-β and pdgf from dysplastic megakaryocytes.15 the differential diagnosis includes myelofibrosis with myeloid metaplasia, chronic myelocytic leukemia and acute megakaryocytic leukemia. |
| PubMedID- 23457485 | Exclusion criteria were prior chronic renal dysfunction, previously treated malignancy (>4 weeks after the first chemotherapy dose), relapsing or refractory hematological malignancy, bone marrow or stem cell transplantation, low-grade or chronic malignancy (chronic myelogenous leukemia, chronic lymphocytic leukemia, low-grade nhl, multiple myeloma, myelodysplastic syndrome, myelofibrosis with myeloid metaplasia, or aplastic anemia), and absence of potentially lifespan-extending treatment options. |
| PubMedID- 23259545 | myelofibrosis with myeloid metaplasia (mmm) is a rare malignant hematological disease of the hematopoietic stem cells with a median age at diagnosis of 60 years. |
| PubMedID- 20359349 | Clonal dysregulation linked to myeloproliferative neoplasms (mpn) arising from acquired mutations in the haematopoietic progenitor cells lead to a wide range of clonal haematological malignant diseases including polycythemia vera (pv), essential thrombocythemia (et), myeloid metaplasia with myelofibrosis (mmm), chronic myelomonocytic leukemia (cmml), chronic myelogenous leukemia (cml), hypereosinophilic syndrome (hes), and systemic mast cell disease (smcd)[1]. |
| PubMedID- 22548075 | Most of the reported pulmonary extramedullary hematopoiesis is seen in myelofibrosis with myeloid metaplasia, a subgroup of chronic myeloproliferative disorders. |
| PubMedID- 24744667 | Also suggested that pv patients homozygous for jak2v617f are more prone to transformation into myelofibrosis with myeloid metaplasia. |
| PubMedID- 23756559 | An increase in circulating cd34+ cells has been described in myelofibrosis with myeloid metaplasia in adults (30) and in raeb in adults (31) and in children, associated with a low apoptotic rate (25). |
Page: 1